Market Cap N/A
Revenue (ttm) 46.92M
Net Income (ttm) -38.10M
EPS (ttm) N/A
PE Ratio N/A
Forward PE 0.00
Profit Margin -81.20%
Debt to Equity Ratio N/A
Volume 775,700
Avg Vol 145,364
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 80%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclero...

Industry: Biotechnology
Sector: Healthcare
Phone: 778-731-1711
Website: nervgen.com
Address:
112-970 Burrard Street, Unit 1290, Vancouver, Canada
jbh973
jbh973 Jul. 24 at 6:23 PM
Thanks to a case of mistaken identity at the naval yard in Lodi, NJ, I am now in possession of a Columbia class ballistic missile submarine. It was hell trying to sail outta the Passaic river to reach the Atlantic, & it took 1 incorrectly pushed button to put an end to the township of Ridgefield Park NJ, but finally made it to the open seas & currently on the lookout for the yachts of @Stephen400 & @JuliusCoolius. So let's raise the periscope with THE MIDDAY STOCK MARKET REVIEW ( The sometimes it's not only October that is Red Edition ) $NGEN Thanks to a couple of smart fellas, I'm going to look like a genius in a few months. After I resurface of course. $LKNCY Been some rough waters recently, but back on course. $DX Thanks to my neighbor Mrs.Snootpiddle leaving her door unlocked to walk Fifi, I was able to add more here today. $SPCX If these guys were building the Titanic II they wouldn't need the iceburg. $AMZN If I can find 5 Amazon delivery people who speak English I'll buy shares. 😀
1 · Reply
MarianoItaliano
MarianoItaliano Jul. 24 at 3:30 PM
$NGEN Somehow I’ve ended up in having 40% of my portfolio in hands of folks from $SRPT (20/20) I’m hoping for some new ”paypal mafia” to emerge from this lol
1 · Reply
OldManLogan
OldManLogan Jul. 24 at 12:57 PM
$NGEN As others said, what specifically is it that management is doing or failing to do at this point? I get the sense from people I've talked to in the industry that management is quietly executing behind the scenes and getting the proper team in place to ensure success. This is a 100% timing issue; it's not like management decided they didn't want to do a phase 3 after all or expand into other indication, lol. Paytience.
4 · Reply
Skaped
Skaped Jul. 24 at 11:36 AM
$NGEN I don't remember seeing this on here earlier... another former Sarepta employee.
1 · Reply
Richardo8586
Richardo8586 Jul. 23 at 8:20 PM
$NGEN we are trying to row to get the ship to shore while I seems to me management is drilling a hole in the bottom. I appreciate the enthusiasm of a lot of people, but I'm very dejected as of now. Keep up the cheerleading though
2 · Reply
Thatcher123
Thatcher123 Jul. 23 at 8:07 PM
$NGEN Is it true that Dr. Dan Mickol has been asked to design the Phase 3 trial for Nervgen?
4 · Reply
Skaped
Skaped Jul. 23 at 7:09 PM
$NGEN Another thing to note... NervGen snuck in some updates to the May PPTX without updating to July. Seems they're softening the wording for the additional indications. https://nervgen.com/wp-content/uploads/2026/07/NervGen-May-2026-Corporate-Presentation-for-Website-20260521_Non-Confidential-vFFF.pdf
3 · Reply
Tarquinjones
Tarquinjones Jul. 23 at 7:03 PM
3 · Reply
Skaped
Skaped Jul. 23 at 6:55 PM
$NGEN Nothing big, but this webpage was updated/corrected in the last day or two. https://shepherd.org/research-innovation/redefining-rehab/find-studies/nervegen-restore-phase-3/
1 · Reply
Tarquinjones
Tarquinjones Jul. 23 at 4:48 PM
$NGEN bring on the squeeze
0 · Reply
Latest News on NGEN
NervGen Pharma initiated with an Outperform at Leerink

2026-07-13T11:45:36.000Z - 11 days ago

NervGen Pharma initiated with an Outperform at Leerink


NervGen Pharma initiated with a Buy at TD Cowen

2026-06-11T09:51:08.000Z - 6 weeks ago

NervGen Pharma initiated with a Buy at TD Cowen


NervGen Pharma files $250M mixed securities shelf

2026-05-26T13:28:30.000Z - 2 months ago

NervGen Pharma files $250M mixed securities shelf


NervGen Pharma Registration statement: Registration filing

May 26, 2026, 8:00 AM EDT - 2 months ago

NervGen Pharma Registration statement: Registration filing


NervGen Pharma 24M share Spot Secondary priced at $2.50

2026-05-22T10:31:38.000Z - 2 months ago

NervGen Pharma 24M share Spot Secondary priced at $2.50


NervGen Pharma secondary being re-offered at $2.50 per share

2026-05-21T23:20:11.000Z - 2 months ago

NervGen Pharma secondary being re-offered at $2.50 per share


NervGen Pharma announces common share offering, no amount given

2026-05-21T20:06:04.000Z - 2 months ago

NervGen Pharma announces common share offering, no amount given


NervGen Announces Proposed Public Offering of Securities

May 21, 2026, 4:01 PM EDT - 2 months ago

NervGen Announces Proposed Public Offering of Securities


NervGen Pharma Slides: Corporate presentation

May 21, 2026, 7:00 AM EDT - 2 months ago

NervGen Pharma Slides: Corporate presentation


NervGen Pharma reports Q1 EPS (2c), consensus (7c)

2026-05-18T11:26:55.000Z - 2 months ago

NervGen Pharma reports Q1 EPS (2c), consensus (7c)


NervGen Pharma Earnings release: Q1 2026

May 18, 2026, 7:00 AM EDT - 2 months ago

NervGen Pharma Earnings release: Q1 2026


NervGen Pharma appoints Keith Vendola as CFO

2026-04-27T11:49:46.000Z - 3 months ago

NervGen Pharma appoints Keith Vendola as CFO


NervGen Pharma initiated with a Buy at H.C. Wainwright

2026-04-27T10:13:14.000Z - 3 months ago

NervGen Pharma initiated with a Buy at H.C. Wainwright


NervGen Pharma Transcript: HCW Home with NervGen Conference

Apr 15, 2026, 7:00 AM EDT - 3 months ago

NervGen Pharma Transcript: HCW Home with NervGen Conference


NervGen Pharma initiated with a Buy at Lucid Capital

2026-04-15T10:11:00.000Z - 3 months ago

NervGen Pharma initiated with a Buy at Lucid Capital


NervGen Pharma price target raised to $12 from $10 at Maxim

2026-04-08T19:20:16.000Z - 3 months ago

NervGen Pharma price target raised to $12 from $10 at Maxim


NervGen Pharma Annual report: Q4 2025

Mar 31, 2026, 8:00 AM EDT - 4 months ago

NervGen Pharma Annual report: Q4 2025


NervGen Pharma Earnings release: Q4 2025

Mar 31, 2026, 8:00 AM EDT - 4 months ago

NervGen Pharma Earnings release: Q4 2025


NervGen Pharma to delist shares from TSX

2026-03-12T21:20:54.000Z - 4 months ago

NervGen Pharma to delist shares from TSX


NervGen Pharma price target raised to C$6.75 from C$5 at Stifel

2026-03-05T17:15:53.000Z - 5 months ago

NervGen Pharma price target raised to C$6.75 from C$5 at Stifel


NervGen Pharma to Participate at Upcoming Investor Conferences

Feb 18, 2026, 7:30 AM EST - 5 months ago

NervGen Pharma to Participate at Upcoming Investor Conferences


NervGen Pharma Begins Trading on Nasdaq Today

Jan 8, 2026, 6:30 AM EST - 7 months ago

NervGen Pharma Begins Trading on Nasdaq Today


NervGen Pharma Registration statement: Registration filing

Jan 7, 2026, 7:00 AM EST - 7 months ago

NervGen Pharma Registration statement: Registration filing


NervGen Pharma Registration statement: Registration filing

Dec 17, 2025, 7:00 AM EST - 7 months ago

NervGen Pharma Registration statement: Registration filing


NervGen Pharma Announces Proposed Amendment to Warrants

Dec 12, 2025, 7:51 PM EST - 7 months ago

NervGen Pharma Announces Proposed Amendment to Warrants


NervGen Pharma Earnings release: Q3 2025

Nov 25, 2025, 7:00 AM EST - 8 months ago

NervGen Pharma Earnings release: Q3 2025


NervGen Pharma Earnings release: Q2 2025

Aug 26, 2025, 7:00 AM EDT - 11 months ago

NervGen Pharma Earnings release: Q2 2025


NervGen Pharma Grants Stock Options

May 16, 2025, 4:30 PM EDT - 1 year ago

NervGen Pharma Grants Stock Options


NervGen Pharma Earnings release: Q1 2025

May 15, 2025, 7:00 AM EDT - 1 year ago

NervGen Pharma Earnings release: Q1 2025


NervGen Pharma Earnings release: Q4 2024

Apr 3, 2025, 7:00 AM EDT - 1 year ago

NervGen Pharma Earnings release: Q4 2024


NervGen Initiates Expanded Access Policy

Mar 31, 2025, 7:30 AM EDT - 1 year ago

NervGen Initiates Expanded Access Policy


NervGen Pharma to Host Virtual Investor Event

Mar 25, 2025, 8:30 AM EDT - 1 year ago

NervGen Pharma to Host Virtual Investor Event


NervGen Announces "At-The-Market" Equity Program

Dec 20, 2024, 7:30 AM EST - 1 year ago

NervGen Announces "At-The-Market" Equity Program


NervGen Pharma Earnings release: Q3 2024

Nov 14, 2024, 7:00 AM EST - 1 year ago

NervGen Pharma Earnings release: Q3 2024


NervGen Pharma Earnings release: Q2 2024

Aug 22, 2024, 7:00 AM EDT - 2 years ago

NervGen Pharma Earnings release: Q2 2024


jbh973
jbh973 Jul. 24 at 6:23 PM
Thanks to a case of mistaken identity at the naval yard in Lodi, NJ, I am now in possession of a Columbia class ballistic missile submarine. It was hell trying to sail outta the Passaic river to reach the Atlantic, & it took 1 incorrectly pushed button to put an end to the township of Ridgefield Park NJ, but finally made it to the open seas & currently on the lookout for the yachts of @Stephen400 & @JuliusCoolius. So let's raise the periscope with THE MIDDAY STOCK MARKET REVIEW ( The sometimes it's not only October that is Red Edition ) $NGEN Thanks to a couple of smart fellas, I'm going to look like a genius in a few months. After I resurface of course. $LKNCY Been some rough waters recently, but back on course. $DX Thanks to my neighbor Mrs.Snootpiddle leaving her door unlocked to walk Fifi, I was able to add more here today. $SPCX If these guys were building the Titanic II they wouldn't need the iceburg. $AMZN If I can find 5 Amazon delivery people who speak English I'll buy shares. 😀
1 · Reply
MarianoItaliano
MarianoItaliano Jul. 24 at 3:30 PM
$NGEN Somehow I’ve ended up in having 40% of my portfolio in hands of folks from $SRPT (20/20) I’m hoping for some new ”paypal mafia” to emerge from this lol
1 · Reply
OldManLogan
OldManLogan Jul. 24 at 12:57 PM
$NGEN As others said, what specifically is it that management is doing or failing to do at this point? I get the sense from people I've talked to in the industry that management is quietly executing behind the scenes and getting the proper team in place to ensure success. This is a 100% timing issue; it's not like management decided they didn't want to do a phase 3 after all or expand into other indication, lol. Paytience.
4 · Reply
Skaped
Skaped Jul. 24 at 11:36 AM
$NGEN I don't remember seeing this on here earlier... another former Sarepta employee.
1 · Reply
Richardo8586
Richardo8586 Jul. 23 at 8:20 PM
$NGEN we are trying to row to get the ship to shore while I seems to me management is drilling a hole in the bottom. I appreciate the enthusiasm of a lot of people, but I'm very dejected as of now. Keep up the cheerleading though
2 · Reply
Thatcher123
Thatcher123 Jul. 23 at 8:07 PM
$NGEN Is it true that Dr. Dan Mickol has been asked to design the Phase 3 trial for Nervgen?
4 · Reply
Skaped
Skaped Jul. 23 at 7:09 PM
$NGEN Another thing to note... NervGen snuck in some updates to the May PPTX without updating to July. Seems they're softening the wording for the additional indications. https://nervgen.com/wp-content/uploads/2026/07/NervGen-May-2026-Corporate-Presentation-for-Website-20260521_Non-Confidential-vFFF.pdf
3 · Reply
Tarquinjones
Tarquinjones Jul. 23 at 7:03 PM
3 · Reply
Skaped
Skaped Jul. 23 at 6:55 PM
$NGEN Nothing big, but this webpage was updated/corrected in the last day or two. https://shepherd.org/research-innovation/redefining-rehab/find-studies/nervegen-restore-phase-3/
1 · Reply
Tarquinjones
Tarquinjones Jul. 23 at 4:48 PM
$NGEN bring on the squeeze
0 · Reply
jbh973
jbh973 Jul. 23 at 4:18 PM
YEEEOIKES!!! It ain't pretty out there in Marketville today folks. Let's take a peek at a few of the Good, the Bad, & the Fugly with... THE MIDDAY STOCKMARKET REVIEW ( The Sometimes all u need is a well aimed peashooter to win a horse race Edition ) $NGEN Still have a boot on my neck here but I'm certain patience will be rewarded. 6 months from now recent buyers should be very happy. $LKNCY I've never climbed Brokeback Mountain but when it comes to Luckin, I just can't quit u. $DX Unless they cut their divy by 98% I see this as THE buying opportunity of the month. Adding like a beast today. $TSLA I don't care if your car is able to drive underwater straight to the wreck of the Titanic, but when yer ticker is down around 50 bucks a share in 1 day u just hit an iceberg. $SPCX I can't help but wonder if Elon Musk is making his trillions just by shorting his own stocks. 😀
1 · Reply
OldManLogan
OldManLogan Jul. 23 at 2:46 PM
$NGEN I am 100% confident that one day I'll feel truly blessed that NGEN stayed this low, this long, so that I could gobble up as much as I want, but in this very moment I feel like the guy that found a sandwich under the couch that he thought he lost a couple months earlier... lol. All good things come to those who wait.
1 · Reply
Tarquinjones
Tarquinjones Jul. 23 at 1:33 PM
$NGEN https://www.youtube.com/live/DhDC0DAYdBI?is=EsGJ9Y0uDUVyddpz
3 · Reply
OldManLogan
OldManLogan Jul. 23 at 1:32 PM
$NGEN Yes, you should probably stick to $TSLA ... but come back and year from today and we can compare notes...
0 · Reply
Zeppieddodaw
Zeppieddodaw Jul. 23 at 1:14 PM
$NGEN FDA panel meeting on peptides this week. Although not directly related to Nvg 291 the outcome could indirectly impact regulatory climate. CNN article.
0 · Reply
alexandredaigneault96
alexandredaigneault96 Jul. 22 at 8:12 PM
$NGEN extremely pathetic display of pretty much everything. My patience is done.. How do we contact the board of directors?? We need accountability enough is enough. They have done more a piss poor job in all aspects then I could ever imagine. It's like they are trying to piss off investors. How do we contact the board of directors. They need to fire the management. A delay in phase 3 which they said would start now would be the drop in the bucket. Enough is enough. 70% dip in stock price in 6 months since these 2 doodo heads we're hired is all there needs to be said ..!
4 · Reply
TSLA_S3XY
TSLA_S3XY Jul. 22 at 8:10 PM
$NGEN Glad I Never Bought Into This Pipe Dream
2 · Reply
jbh973
jbh973 Jul. 22 at 7:09 PM
$NGEN Went full throttle & purchased a 0.0000528974 fractional share this morning. I gotta be honest, I don't like how this is looking so far....
0 · Reply
harambe_reborn
harambe_reborn Jul. 22 at 6:48 PM
$NGEN grabbed some 1.70s today ez hold
0 · Reply
ONLYPHARMS
ONLYPHARMS Jul. 22 at 4:46 PM
$NGEN I know phase 3 is supposed to start anytime there any word and when the interim details for that phase will be announced 
0 · Reply
OldManLogan
OldManLogan Jul. 22 at 3:45 PM
$NGEN I would agree that day to day movements are irrelevant unless you are active in the market, which I am, but just putting the sprinkles on the cake at this point. Where I would disagree is on the boom or bust part... we are so beaten up compared to fair value that someone could buy today and sell half for a 100% gain in a few months and then let the rest of the house money ride effectively risk free. Also think that even if p3 results aren't as robust as phase 2, company could still try for an approval given the total lack of alternatives for SCI... to be clear, my base assumption is that p3 is successful, just trying to say it's less binary than some other clinical bios.
0 · Reply
Mikavelli17
Mikavelli17 Jul. 22 at 2:18 PM
$NGEN Just a reminder, this stock is 100% boom or bust. If the drug continues working, as it has in every application tried thus far, FDA will approve and stock will moon. If it fails, stock tanks into nothing. So please, stop whining about day to day movements, shaking your fist at CEO/CFO, none of that really matters. Yes dilution hurt and probably could have been done better but p3 funding now secure and we are on our way. If you are looking for a security with linear improvements, there are 10k better options than a tiny, obscure bio pharma co, potentially on the edge of greatness. Personally I am glad NGEN team is not out there boasting about trial results and investment potential. That would be just a distraction from the only thing that really matters here, FDA approval. I believe we see that in 2027, stock moons, and NGEN either establishes neuro franchise or sells to big boys. Believe in the science, hold your chips, and wait for the river card fellas.
3 · Reply